Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
NCT ID: NCT03435120
Last Updated: 2020-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
118 participants
OBSERVATIONAL
2017-12-21
2020-02-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent
NCT02836379
Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units
NCT02840500
Observational Study of Incidence of Breakthrough Cancer Pain and How it is Treated
NCT02069067
Cognitive Stimulation and Chemobrain. An Innovative Intervention for Cancer Survivors
NCT05409248
Vulnerability and Risk of Neuropathic Pain in Cancer
NCT06511674
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breakthrough Cancer Pain
No intervention (Non Interventional Study)
No intervention
No intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with histologically confirmed neoplasia
* Patients attended in medical oncology consultations
* Life expectancy \> 3 months
* Patients with baseline controlled cancer pain with opioids who are diagnosed of breakthrough cancer pain by Davies algorithm
* Written informed consent
Exclusion Criteria
* Patients who are not opioid tolerant
* Serious psychiatric disorder or any disease or condition that prevents the collection of data
* Patients with evidence of opioid addiction or history of drug or alcohol abuse
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Apices Soluciones S.L.
INDUSTRY
Angelini Farmacéutica
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carlos Camps Herrero
Role: PRINCIPAL_INVESTIGATOR
Hospital General Universitario de Valencia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Complexo Hospitalario Universitario de Santiago
Santiago de Compostela, A Coruña, Spain
Hospital Principe de Asturias
Alcalá de Henares, Madrid, Spain
Hospital Universitari Son Espases
Palma de Mallorca, Palma, Spain
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain
Hospital Universitari de San Joan de Reus
Reus, Tarragona, Spain
Hospital Verge de la Cinta
Tortosa, Tarragona, Spain
Hospital San Pedro de Alcántara
Cáceres, , Spain
Hospital Arnau de Vilanova
Lleida, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital Ramón y Cajal
Madrid, , Spain
Hospital Clínico San Carlos
Madrid, , Spain
Hospital Universitario de Salamanca
Salamanca, , Spain
Hospital Alvaro Cunqueiro
Vigo, , Spain
Hospital Universitario Miguel Servet
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANG-ANA-2017-01 (CAVIDIOM)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.